{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:27:24Z","timestamp":1787502444761,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The ARTEMIS Global Antifungal Susceptibility Program (ARTEMIS Program) was initiated in 2001 to provide focused surveillance of the activities of fluconazole and voriconazole against\n                    <jats:italic>Candida<\/jats:italic>\n                    spp. isolated from blood and other normally sterile sites. A total of 1,586 episodes of infection were detected at 61 international study sites. Overall, 57.7% of the infections were due to\n                    <jats:italic>Candida albicans<\/jats:italic>\n                    , followed by\n                    <jats:italic>C. glabrata<\/jats:italic>\n                    (14.8%),\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    (12.5%),\n                    <jats:italic>C. tropicalis<\/jats:italic>\n                    (9.4%),\n                    <jats:italic>C. krusei<\/jats:italic>\n                    (2.7%), and\n                    <jats:italic>C. lusitaniae<\/jats:italic>\n                    (1.5%). Isolates of\n                    <jats:italic>C. albicans<\/jats:italic>\n                    ,\n                    <jats:italic>C. parapsilosis<\/jats:italic>\n                    , and\n                    <jats:italic>C. tropicalis<\/jats:italic>\n                    were all highly susceptible to fluconazole (for 99% of the isolates the MICs were \u22648 \u03bcg\/ml). Likewise, 99 to 100% of these species were inhibited by \u22641 \u03bcg of voriconazole per ml. Voriconazole was also active against\n                    <jats:italic>C. glabrata<\/jats:italic>\n                    (93% of the isolates were susceptible [MICs \u2264 1 \u03bcg\/ml]) and\n                    <jats:italic>C. krusei<\/jats:italic>\n                    (100% of the isolates were susceptible). The agar-based Etest and disk diffusion methods performed well for the testing of both fluconazole and voriconazole compared to the broth microdilution MIC reference method. These observations establish the continued importance of\n                    <jats:italic>C. albicans<\/jats:italic>\n                    as a pathogen and the sustained activity of fluconazole and the broad spectrum of activity of voriconazole and will serve as the first-year benchmark for the ARTEMIS Program. Continued surveillance and refinement of broth- and agar-based test methods will help to identify susceptibility trends and improve the laboratory capability for antifungal susceptibility testing.\n                  <\/jats:p>","DOI":"10.1128\/jcm.41.4.1440-1446.2003","type":"journal-article","created":{"date-parts":[[2003,4,7]],"date-time":"2003-04-07T16:34:54Z","timestamp":1049733294000},"page":"1440-1446","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":146,"title":["Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of\n                    <i>Candida<\/i>\n                    Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001"],"prefix":"10.1128","volume":"41","author":[{"given":"M. A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"Departments of Pathology"},{"name":"Epidemiology, Roy J. and Lucille A. Carver College of Medicine and College of Public Health, University of Iowa, Iowa City, Iowa 52242"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Diekema","sequence":"additional","affiliation":[{"name":"Departments of Pathology"},{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Messer","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boyken","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Hollis","sequence":"additional","affiliation":[{"name":"Departments of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.9.3457-3459.2000"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1781-1784.2002"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.3.531-537.1999"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.11.4181-4183.2001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/mmy.38.s1.173.182"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Ernst E. J. 2001. Investigational antifungal agents. Pharmacotherapy 21 (Pt. 2) : 165S-174S.","DOI":"10.1592\/phco.21.12.165S.34509"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.3.345"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.17"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00121-6"},{"key":"e_1_3_2_11_2","first-page":"1","volume":"46","year":"2000","unstructured":"Jones, R. N., and the MYSTIC Advisory Board. 2000. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. J. Antimicrob. Chemother.46(Topic T2):1-8.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.11.3429-3432.1998"},{"key":"e_1_3_2_13_2","first-page":"1917","volume":"44","year":"2002","unstructured":"Klepser, M. E., D. Malone, R. E. Lewis, E. J. Ernest, and M. A. Pfaller. 2002. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother.44:1917-1920.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.4.1422-1428.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.25"},{"key":"e_1_3_2_16_2","first-page":"3","volume":"49","year":"2002","unstructured":"Lewis, D. 2002. Antimicrobial resistance surveillance: methods will depend on objectives. J. Antimicrob. Chemother.49:3-5.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_17_2","first-page":"53","volume":"46","year":"2000","unstructured":"Masterton, R. G. 2000. Surveillance studies: how can they help the management of infection? J. Antimicrob. Chemother.46(Topic T2):53-58.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00152-2"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.suppl_1.7"},{"key":"e_1_3_2_20_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_21_2","unstructured":"National Committee for Clinical Laboratory Standards. 2003. Method for antifungal disk diffusion susceptibility testing of yeasts: proposed guideline M44-P. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.2.303"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/27.5.1148"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.9.2586-2589.1998"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(98)00160-6"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.747-751.2000"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.10.3715-3717.2000"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3254-3259.2001"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70192-6"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.643-658.2001"},{"key":"e_1_3_2_33_2","first-page":"304","volume":"67","year":"2001","unstructured":"Richet, H. M. 2001. Better antimicrobial resistance surveillance efforts are needed. ASM News67:304-309.","journal-title":"ASM News"},{"key":"e_1_3_2_34_2","first-page":"3","volume":"71","year":"1997","unstructured":"Ruchel, R. 1997. Recurrence of Candida albicans? ISHAM Mycoses Newsl.71:3.","journal-title":"ISHAM Mycoses Newsl."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.12.3455-3459.1998"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.1.40"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.3.949-953.2001"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/322641"},{"key":"e_1_3_2_39_2","unstructured":"Warren N. G. and K. C. Hazen. 1999. Candida Cryptococcus and other yeasts of medical importance p. 1184-1199. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. ASM Press Washington D.C."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.4.1440-1446.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.4.1440-1446.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T21:14:55Z","timestamp":1646428495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.41.4.1440-1446.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1128\/JCM.41.4.1440-1446.2003"],"URL":"https:\/\/doi.org\/10.1128\/jcm.41.4.1440-1446.2003","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"2002-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}